康柏西普预处理联合玻璃体切割术治疗增生型糖尿病视网膜病变

目的 探讨抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物康柏西普对增生型糖尿病视网膜病变(proliferative diabetic retinopathy,PDR)患者玻璃体切割术(pars plana vitrectomy,PPV)术中和术后的影响.方法 将2016年1月至12月于我科确诊PDR伴有玻璃体出血(vitreous hemorrhage,VH)和(或)牵拉性视网膜脱离(tractional retinal detach-ment,TRD)的123例149眼患者纳入研究,其中康柏西普组64例78眼,对照组59例71眼.康柏西普组于PPV术前3d玻璃体内注射抗VEGF药物0.50 mg(0.05 mL),对照组无处理.无明显并发症后2组行标准23G微创巩膜三通道玻璃体切割术,记录并分析手术时间、术中出血、医源性视网膜裂孔、眼内电凝使用、是否硅油填充等,对术前及术后1个月视力及黄斑厚度进行对比,观察术后并发症情况.结果 两组患者年龄、性别、糖化血红蛋白、糖尿病病程,VH≥Ⅲ级眼数(56/78、45/71),术前TRD比较均无明显差异.康柏西普预处理可明显降低PPV术中出血(43/78、49/71)、医源性视网膜裂孔的概率(11/78、21/71),减少眼内电凝使用(57/78、62/71)及硅油填充(43/78、51/71),进而缩短手术时间(58.63±21.66)s、(72.69±22.48)s,且其可明显改善术后视力(0.23±0.15,0.16±0.11)及黄斑水肿厚度(260.95±27.44) μm、(330.81±36.62) μm,同时降低二次积血发生率(3/78、10/71).结论 康柏西普预处理联合PPV是治疗PDR患者一项积极有效的治疗方案.

Conbercept pre-treatment combined with vitrectomy for proliferative diabetic retinopathy

Objective To discuss the intraoperative and postoperative effects of conbercept combined with pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR) patients.Methods From January 2016 to December 2016,123 PDR patients (149 eyes) aged 41-65 years old with nonclearing vitreous hemorrhage (VH) and/or tractional retinal detachment (TRD) were enrolled in this study.According to whether preoperative intravitreal injection conbercept,the patients were divided into two groups:Conbercept group (64 cases,78 eyes),Control group (59 cases,71 eyes).Conbercept group was treated with intravitreal injection of Conbercept 0.50 mg (0.05 mL) at 3 days before PPV.Then the standard 23G minimally invasive sclera three-channel vitrectomy was performed if no significant complications after the injection of conbercept.The operation time,intraoperative bleeding,iatrogenic retinal hole,use of endodiathermy and silicone oil,and postoperative complications were recorded and analyzed.The visual acuity and macuiar thickness were compared before and 1 month after the surgery.Results Two groups had no difference on age,sex,HbA1 C,duration,VH ≥ three degree(56/78,45/71),TRD.Conbercept pretreatment could significantly reduce the bleeding during PPV (43/78,49/71),the probability of iatrogeuic retinal holes (11/78,21/71),reduce intraocular electrocoagulation using (57/78,62/71) and silicone oil (43/78,51/71),and then shorten the operation time (58.63 ± 21.66)s and (72.69 ± 22.48)s,and it could significantly improve the postoperative visual acuity (0.23 ± 0.15,0.16 ± 0.11) and macular edema thickness (260.95 ± 27.44) μm and (330.81 ± 36.62)μm,while reduce the incidence of second bleeding (3/78,10/71).Conclusion Conbercept pre-treatment combined with PPV for PDR is a positive and effective treatment,which has good clinical application significance.